Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients

Phase 2

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: AZD1775

First Posted Date: 2015-10-30

Last Posted Date: 2021-03-19

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 24

Registration Number: NCT02593019

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Genetic Alteration After Systemic Treatment in Breast Cancer

Conditions: Breast Cancer

First Posted Date: 2015-10-30

Last Posted Date: 2018-01-18

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 350

Registration Number: NCT02591966

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Phase 2 Study of Gemcitabine and Docetaxel Combination Chemotherapy in Patients With Carcinoma of Unknown Primary

Phase 2

Conditions: Carcinoma of Unknown Primary

Interventions: Drug: gemcitabine/docetaxel combination

First Posted Date: 2015-10-28

Last Posted Date: 2015-10-28

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 29

Registration Number: NCT02590055

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Pemetrexed Alone as Salvage Treatment in Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy: A Phase II Single Arm Prospective Study

Phase 2

Conditions: Colorectal Cancer

Interventions: Drug: Pemetrexed

First Posted Date: 2015-10-28

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 23

Registration Number: NCT02588781

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis

Phase 2

Completed

Conditions: Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma

Interventions: Drug: pembrolizumab

First Posted Date: 2015-10-28

Last Posted Date: 2023-05-09

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 80

Registration Number: NCT02589496

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Korea, Republic of

Use of Transexamic Acid in Hip Replacement

Phase 3

Conditions: Bleeding
Transfusion Related Complication

Interventions: Drug: Tranexamic Acid (IV)
Drug: Tranexamic Acid (Topical)

First Posted Date: 2015-10-27

Last Posted Date: 2015-10-27

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 150

Registration Number: NCT02587845

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Myocardial Flow Reserve in Severe AS Without Obstructive Coronary Artery Disease

Completed

Conditions: Severe Aortic Stenosis
Chest Pain

Interventions: Other: Adenosine-stress cardiac magnetic resonance imaging

First Posted Date: 2015-10-15

Last Posted Date: 2015-10-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 104

Registration Number: NCT02575768

Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Not Applicable

Completed

Conditions: Proton Therapy
Liver Neoplasm
Portal Vein Tumor Thrombosis

Interventions: Radiation: Proton beam therapy

First Posted Date: 2015-10-08

Last Posted Date: 2023-11-22

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 53

Registration Number: NCT02571946

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

Phase 2

Conditions: Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck

Interventions: Drug: BIBF1120

First Posted Date: 2015-09-24

Last Posted Date: 2015-11-20

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 20

Registration Number: NCT02558387

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Prospective Registration of Head and Neck Cancer

Recruiting

Conditions: Head and Neck Cancer

First Posted Date: 2015-09-11

Last Posted Date: 2023-11-27

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 2000

Registration Number: NCT02546895

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy